In November of 2014, Apellis Pharmaceuticals acquired Potentia Pharmaceuticals. Potentia Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing innovative therapeutics primarily in the area of age-related macular degeneration and other inflammatory ocular diseases. Potentia assembles its pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development.